First preservative-free prostaglandin treatment approved

Article

Taflotan (tafluprost; Santen Oy), a benzalkonium chloride (BAK)-free prostaglandin analogue for the treatment of glaucoma, has received marketing authorization in Denmark and Germany, making it the first preservative-free prostaglandin eye drop to be approved.

Taflotan (tafluprost; Santen Oy), a benzalkonium chloride (BAK)-free prostaglandin analogue for the treatment of glaucoma, has received marketing authorization in Denmark and Germany, making it the first preservative-free prostaglandin eye drop to be approved.

Taflotan has been shown to be reduce intraocular pressure by 27–31% in open angle glaucoma and ocular hypertension, with hyperaemia as the most commonly reported adverse event (13%).

Taflotan is indicated as monotherapy for patients who are intolerant to or contraindicated for first-line treatment, and as an adjunct to beta-blockers. It is especially recommended for patients who might suffer BAK-related side effects, such as those with dry or sensitive eyes.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.